CR2 | Complement component (3d/Epstein Barr virus) receptor 2 | CD markers Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
OTOA | Otoancorin | Disease related genes Predicted secreted proteins
| | | | | Group enriched |
CD5L | CD5 molecule-like | Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
FCER2 | Fc fragment of IgE, low affinity II, receptor for (CD23) | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Group enriched |
MS4A1 | Membrane-spanning 4-domains, subfamily A, member 1 | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
CD19 | CD19 molecule | CD markers Disease related genes Predicted membrane proteins
| | | | | Group enriched |
FCRLA | Fc receptor-like A | Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
FAM9C | Family with sequence similarity 9, member C | Predicted membrane proteins
| | | | | Tissue enriched |
NOS3 | Nitric oxide synthase 3 (endothelial cell) | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enriched |
CD72 | CD72 molecule | CD markers Predicted membrane proteins
| | | | | Group enriched |
HLA-DOB | Major histocompatibility complex, class II, DO beta | Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
TNFRSF13C | Tumor necrosis factor receptor superfamily, member 13C | CD markers Disease related genes Predicted membrane proteins
| | | | | Group enriched |
CXCR5 | Chemokine (C-X-C motif) receptor 5 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CCR7 | Chemokine (C-C motif) receptor 7 | Cancer-related genes CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
LTB | Lymphotoxin beta (TNF superfamily, member 3) | Cancer-related genes Plasma proteins
| | | | | Group enriched |
SELL | Selectin L | Cancer-related genes Candidate cardiovascular disease genes CD markers Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
AIF1L | Allograft inflammatory factor 1-like | | | | | | Tissue enhanced |
C5AR2 | Complement component 5a receptor 2 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CD226 | CD226 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD300LF | CD300 molecule-like family member f | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD7 | CD7 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD79B | CD79b molecule, immunoglobulin-associated beta | Cancer-related genes CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
CD8A | CD8a molecule | CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FCGR3A | Fc fragment of IgG, low affinity IIIa, receptor (CD16a) | CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FCRL1 | Fc receptor-like 1 | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GP9 | Glycoprotein IX (platelet) | CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
GPR182 | G protein-coupled receptor 182 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
IGSF21 | Immunoglobin superfamily, member 21 | Predicted secreted proteins
| | | | | Tissue enhanced |
IL2RB | Interleukin 2 receptor, beta | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ITGAX | Integrin, alpha X (complement component 3 receptor 4 subunit) | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
KLRC3 | Killer cell lectin-like receptor subfamily C, member 3 | Predicted membrane proteins
| | | | | Tissue enhanced |
KLRK1 | Killer cell lectin-like receptor subfamily K, member 1 | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
LAG3 | Lymphocyte-activation gene 3 | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
NKG2-E | Uncharacterized protein | Predicted membrane proteins
| | | | | Tissue enhanced |
P2RY13 | Purinergic receptor P2Y, G-protein coupled, 13 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
PITPNM3 | PITPNM family member 3 | Disease related genes
| | | | | Tissue enhanced |
PSTPIP2 | Proline-serine-threonine phosphatase interacting protein 2 | Cytoskeleton related proteins
| | | | | Tissue enhanced |
PTPRCAP | Protein tyrosine phosphatase, receptor type, C-associated protein | Predicted secreted proteins
| | | | | Tissue enhanced |
RENBP | Renin binding protein | Enzymes
| | | | | Tissue enhanced |
SHANK3 | SH3 and multiple ankyrin repeat domains 3 | | | | | | Tissue enhanced |
SIGLEC14 | Sialic acid binding Ig-like lectin 14 | Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
SIGLEC5 | Sialic acid binding Ig-like lectin 5 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
SLC9A5 | Solute carrier family 9, subfamily A (NHE5, cation proton antiporter 5), member 5 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
TBX21 | T-box 21 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
VCAM1 | Vascular cell adhesion molecule 1 | Cancer-related genes CD markers Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |